WeLeader Biomedical Co

WeLeader Biomedical Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of WeLeader Biomedical Co (7713.TWO) as of Oct 25, 2026 is 4.91. In the previous year, Net Debt to Free Cash Flow Ratio was 3.81 — a change of 28.83% (higher).

Net Debt/FCF

4.91

YoY

28.83%

Last updated:

Net Debt to Free Cash Flow Ratio of WeLeader Biomedical Co is 2025 4.91 . Net Debt to Free Cash Flow Ratio of WeLeader Biomedical Co was 2024 3.81 . It decreases by 28.83% higher compared to the previous year.

The WeLeader Biomedical Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2020
2.42 TWD
Jan 1, 2021
0.09 TWD
Jan 1, 2022
-0.71 TWD
Jan 1, 2023
2.14 TWD
Jan 1, 2024
3.81 TWD
Jan 1, 2025
4.91 TWD
The WeLeader Biomedical Co Net Debt/FCF history
YEARNet Debt/FCFYoY
4.91+28.83%
3.81+77.60%
2.14-402.64%
-0.71-913.37%
0.09-96.40%
2.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Net Debt to Free Cash Flow Ratio of WeLeader Biomedical Co is 4.91 in 2025.

Net Debt to Free Cash Flow Ratio of WeLeader Biomedical Co changed from 3.81 to 4.91, representing a 28.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's WeLeader Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — WeLeader Biomedical Co

All Key Metrics — WeLeader Biomedical Co